Cogent Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cogent Biosciences, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2024.
  • Cogent Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $10.4M, a 18.3% increase year-over-year.
  • Cogent Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $38.6M, a 44% increase year-over-year.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $30.6M, a 66.7% increase from 2022.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18.4M, a 57.2% increase from 2021.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.7M, a 94.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $38.6M $10.4M +$1.6M +18.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $37M $10M +$2.85M +39.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $34.2M $9.39M +$3.54M +60.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $30.6M $8.85M +$3.81M +75.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $26.8M $8.76M +$4.14M +89.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $22.7M $7.16M +$2.63M +58% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $20M $5.85M +$1.68M +40.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $18.4M $5.04M +$1.19M +30.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $17.2M $4.62M +$1.16M +33.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $16M $4.53M +$1.94M +75.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $14.1M $4.18M +$2.39M +134% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.7M $3.85M +$2.99M +345% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $8.7M $3.46M -$49K -1.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $8.75M $2.59M +$1.72M +198% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $7.03M $1.78M +$1.01M +132% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $6.02M $866K +$24K +2.85% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 $5.99M $3.51M +$2.72M +346% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $3.27M $870K -$15K -1.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $3.28M $769K +$43K +5.92% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $3.24M $842K -$539K -39% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $3.78M $788K -$72K -8.37% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $3.85M $885K +$38K +4.49% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $3.81M $726K +$726K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $3.09M $1.38M +$921K +200% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 $2.17M $860K +$561K +188% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.61M $847K +$565K +200% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 $1.04M $479* -$300K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 $1.34M $460K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 $299K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $282K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $300K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.